≪Born to be wild oder doch gelernt?≫ Neue verhaltensmedizinische Erkenntnisse zur Atiopathogenese der Migräne

Verhaltenstherapie

Volumn 6, Issue 4, 1996, Pages 210-220

  Gerber, W D ^a   Kropp, P ^a   Schoenen, J ^b   Siniatchkin, M S ^c  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Migr ne; Neurophysiologie; Pathogenese; Verhaltensmedizin

Indexed keywords

EID: 0006469014     PISSN: 10166262     EISSN: 14230402     Source Type: Journal    
DOI: 10.1159/000258991     Document Type: Article

References (111)

1. Abramovitz M, Dubrovsky B: CNV characteristics throughout the normal menstrual cycle: in Kornhuber HH, Decke L (eds): Prog Brain Res 1980;54:441-446.
2. Amery WK, Vandenbergh V: What can precipitating factors teach us about the pathogenesis of migraine? Headache 1987:27:146-150.
3. Antelman S, Chiodo LA: Stress: its effects on interactions among biogenic amines and role in the induction and treatment of disease: in Ivcrsen L, Ivcrsen SD, Snyder S (eds): Landbook of Psychopharmacology, voi 18, New York, Plenum, 1984.
4. Anthony M, Lance JW: Serotonin in migraine: in Pearce JMS (ed): Topics in Migraine, London, Hcine-mann, 1975.
5. Barabas G, Ferrari M, Matthews WS: Childhood migraine and somnabulism, Neurology 1983:33:948-949.
6. Barbiroli B, Montagna P, Concili P, Funicello R, lotti S, Monari L, Pierangeli G, Zaniol P, Lugaresi E: Abnormal brain and muscle energy metabolism shown by 31P magnetic resonance spectroscopy in patients affected by migraine with aura, Neurology 1992:42:1209-1214.
7. Barbiroli B, Montagna P, Coltelli P, Martinelli P, Sac-quegna T, Zaniol P, Lugaresi E: Complicated migraine studied by phosphorus magnetic resonance spectroscopy, Cephalalgia 1990:10:263-272.
8. Barkley GL, Tepley N, Simkins R, Moran J, Welch KMA: Ncuromagnetic fields in migraine: Preliminary findings, Cephalalgia 1990;10:171-176.
9. Barlow CF: Headaches and Migraine in Childhood, Philadelphia, Lippincott, 1984.
10. Besken E, Pothmann R, Sartory G: Contingent negative variation in childhood migraine, Cephalalgia 1993:13:42-43.
11. Biegon A, Rechcs A, Snyder L, McEwen BS: Serotonergic and noradrenergic receptors in rat brain: Modulation by chronic exposure to ovarian hormones, Life Sci 1983:32:2015-2021.
12. Birbaumer N, Elbert T, Canavan A, Rockstroh B: Slow Potentials of the Cerebral Cortex and Behavior, Physiol Rev 1990:70:1-41.
13. Blau IN: Migraine triggers: Practice and theory, Path Biol 1992:40:367-372.
14. Böker KBE, Timsit-Bcrthier M, Sehoenen J, Brunia CUM: Contingent negative variation in migraine, Headache 1990:30:604.
15. Bresolin N, Martinelli P, Barbirolli B, Zaniol P, Ausen-da C, Montagna P, Gallanti A, Comi GP, Scartato G, Lugaresi E: Muscle mitochondrial DNA deletion and 31P-NMR spectroscopy alterations in a migraine patient, J Neurol Sci 1991:104:182-189.
16. Buchsbaum MS, Süvennan J: Stimulus intensive control and the cortical evoked response, Psychosom Med 1968:30:12-22.
17. Calabresi P, Silvestrini M, Strata K Cupini LM, Argiro G, Bernardi G: L-Deprenyl test in migraine: Neuroendocrinological aspects, Cephalalgia 1993:13:406-409.
18. Castillo J, Martine I, Suarez C, Naveiro J, Lema M, Nova M: Cerebrospinal fluid tirosinc and 3,4-dihy-droxyphcnylacelic acid levels in migraine patients Cephalalgia 1996:16:56-61.
19. Dandrea G, Canani AR, Joseph R et al: Platelet glycine glutamate and aspartate in primary headache, Cephalalgia 1991:11: 197-200.
20. DAndrea G, Welch KMA, Riddle JM, Grunfeld S: Platelet serotonin metabolism and ultrastructure in migraine, Arch Neurol 1989:46:1187-1189.
21. DelBene E: Multiple aspects of headache risk in children: in Critchley MD, Friedman AP, Gorini S, Sicuteri F (eds): Adv Neurol 1982:33:187-198.
22. Diener HC, Scholz F, Dichgans J, Gerber WD: Central effects of drugs used in migraine prophylaxis evaluated by visual evoked potentials Ann Neurol 1989: 25:125-130.
23. Flberl T: Slow cortical potentials reflect the regulation of cortical excitability; in McCallum WC, Curry SH (eds): Slow Potentials Changes in the Human Brain, New York, Plenum Press, 1993, pp 235-251.
24. Elbert T, Rockstroh B: llireshold regulation - a key to the understanding the combined dynamics of EEG and event-related potentials, J Psvchophysiol 1987: 4:317-333.
25. Elbert T, Roekstroh B, Lutzenberger W, Birbaumer N: Slow brain potentials after withdrawal of control, Arch Psvchiatr Neurol Sci 1982:232:201-221.
26. Ferrari MD: Systemic biochemistry: in Olesen J, Tfelt-Hansen P, Welch KMA (eds): The Headaches, New York, Raven Press, 1993, pp 179-184.
27. Ferrari MD, Odink J, Bos KD, Malessy MJA, Bruyn GW: Neuroexcitatory plasma amino acids are elevated in migraine, Neurology 1990:40:1582-1586.
28. Ferrari MD, Odink J, Tapparelli C, Van Kempen GMJ, Pennings EJM, Bruyn GW: Serotonin metabolism in migraine, Neurology 1993:39:1239-1242.
29. Fox PT, Raichlc ME, Minium VIA, Dence C: Nonoxi-dative glucose consumption during focal physiological neural activity, Science 1988:241:462-464.
30. Gerber WD, Kropp P: Migräne als Reizverarbeitungsstörung - Empirische Untersuchungen zur Contingen-ten negativen Variation bei Migränepatienten, Schmerz 1993:7:280-286.
31. Göbel H, Krapat S, Ensink FB, Soyka D: Comparison of contingent negative variation between migraine interval and migraine attack before and after treatment with sumatriptan, Headache 1993;33:570-572.
32. Guidetti V, Pagliarini M, Cortesi F, Formisano R, Cer-bo R, Buzzi MG, D'Angelo M, Fioravanti A, Agnoli A: Mothers and children with primary headache: A psychometric and psychological study, Cephalalgia 1985;5(suppl 3): 162-164.
33. Horowski R, Wachtel H, Dorow R: Dopamine as a deuteroagonist in migraine: Implications for clinical pharmacology of dopamine agonists; in Winlow W, Markstein R (eds): The neurobiology of dopamine systems, Manchester, Manchester University Press, 1986, pp 415-427.
34. Joutel A, Bousscr MG, Biousse V: A gene for familial hemiplegic migraine maps to chromosome 19, Nat Genet 1993:5:40-45.
35. Kandel ER: Cellular mechanisms of learning and biological basis of individuality: in Kandel ER, Schwartz JH, Jessell TM (eds): Principles of Neurol Science, New York, Elsevier, 1992, pp 1009-1031.
36. Kennard C, Gawel M, Rudolf N, Clifford Rose F: Visual evoked potentials in migraine subjects, Res Clin Stud Headache 1978;6:73-80.
37. Klopstock K, May A, Seibel P, Papagiannuli E, Diener HC, Reichman H: Mitochondrial DNA in migraine with aura, Neurology 1996:46:1735-1738.
38. Kowal A, Pritchard D: Psychological characteristics of children who suffer from headache: A research note, J Child Psychol Psychiatr 1990:31:637-649.
39. Kropp P, Gerber WD: Is increased amplitude of contingent negative variation in migraine due to cortical hyperactivity or to reduced habituation? Cephalalgia 1993:13:37-41.
40. Kropp P, Gerber WD: Contingent negative variation (CNV) during migraine attack and interval: Evidence for normalization of slow cortical potentials during attack, Cephalalgia 1995:15:123-128.
41. Kropp P, Gerber WD: Contingent negative (CNV) periodicity n migraine - is the migraine attack predictable? (submitted).
42. Lance JW: What is migraine?: in Critchley M, Friedman AP, Gorini S, Sicuteri F (eds): Adv Neurol, New York, Raven Press, 1982, vol 33, pp 21-26.
43. Lance JW: Mechanisms and management of headache, 5th edition, Oxford, Butterworth & Heinemann, 1993.
44. Lucas RN: Migraine in twins, J Psychosom Res 1977:20:147-156.
45. Lvkaitis M: Migräne im Kindesalter, Frankfurt, Peter Lang Verlag, 1986.
46. Macrtensde Noordhout A, Timsit-Bcrthier M, Timsit M, Sehoenen J: Effects of beta-blockade on contingent negative variation in migraine, Ann Neurol 1987: 21:111-112.
47. Magos AL, Brincat M, Zilkha KJ, Studd JW: Serum dopaminc-beta-hydroxylase activity in menstrual migraine, J Neurol Neurosurg Psychiatr 1985:48:328-331.
48. Mazzotta G, Alberti A, Santucci A, Gallai V: The event-related potential P300 during headache-free period and spontaneous attack in adult headache sufferers, Headache 1995:35:210-215.
49. McCallum WC: Potentials related to expectancy, preparation and motor activity: in Picton TW (ed): Human Event-Related Potentials, EEG Handbook, New York, Elsevier Science, 1988, vol 3, pp 427-534.
50. McGiunnoss D, Pribam K: ITie neuropsychology of attention: Emotional and motivational control, London, Academic Press, 1980.
51. Mesulam MM: Large-scale neurocognitive networks and distributed processing for attention language and memory, Ann Neurol 1990:28:597-613.
52. Meyer FB: Calcium, neuronal hyperexcitability and ischemic injury, Brain Res Rev 1989:14:227-243.
53. Miller R: Striatal dopamine in reward and attention: A system for understanding the symptomatology of acute schizophrenia and mania, Int Rev Neurobiol 1993:35:161-278.
54. Miller R, Wickens JR: Corticostriatal cell assemblies in selective attention and in representation of predictable and controllable events, Concepts Neurosci 1991: 2:65-95.
55. Mochi M, Sangiorgi S, Cortelli P, Carelli V, Scapoli C, Crisci M, Monari L, Pierangeli G, Montagna P: Testing models for genetic determination in migraine, Cephalalgia 1993;13:389-394.
56. Mochi M, Sangiorgi S, Cortelli P, Riva R, Crisi M, Monari L, Montagna P, Lugaresi E: Migraine with aura: A threshold character with mitochondrial enzyme deficiency, Necrology 1991;41 (suppl 1):254.
57. Monnier M, Boehmer A, Scholer A: Early habituation, dishabituation and generalization induced in the visual centers by colour stimuli, Vision Res 1976; 16:1479-1504.
58. Montagna P: Magnetic resonance spectroscopy in migraine, Cephalalgia 1995:15:323-327.
59. Montagna P, Sacqucgna T, Cortclli P, Lugaresi E: Migraine as a defect of brain oxidative metabolism: A hypothesis, J Neurol 1989:236:124-125.
60. Montagna P, Sacqucgna T, Martinelli P, Cortelli P, Bre-solin N, et al: Mitochondrial abnormalities in migraine, Preliminary findings, Headache 1988:28:477-480.
61. Montagna P, Cortelli P, Monari L, Pierangeli G, Parchi P, Lodi R, lotti S, Franssineti Zaniol P, Lugaresi E, Barbiroli B: 31P-magnetic resonance spectroscopy in migraine without aura, Neurology 1994:44:666-669.
62. Moskowitz MA: Hie visceral organ brain: Implications for the pathophysiology of vascular head pain, Neurology 1991:41:182-186.
63. Murialdo G, Martignoni E, De Maria A, Sances D, Bono D, Polleri A: Changes in the dopaminergic control of prolactin secretion and in ovarian steroids in migraine, Cephalalgia 1986:6:43-49.
64. Nagel-Leiby S, Welch KMA, D'Andrea CJ, Grunfcid S, Brown E: Event-related slow potentials and associated catecholamine function in migraine, Cephalalgia 1990: 10:317-329.
65. Nvrke T, Kangasniemi P, Lang II: Alpha rhythm in classical migraine (migraine with aura): Abnormalities in the headache-free interval, Cephalalgia 1990:10:177-181.
66. Oades RD: ITie role of noradrenaline in tuning and dopamine in switching between signals in the CNS, Neu-rosci Biobehav Rev 1985:9:261-282.
67. Olds J, Milner P: Positive reeinforcement produced by electrical stimulation of septal area and other regions of rat brain, J Comp Physiol Psychol 1954:47:419-427.
68. Olesen J, Iverscn UK, Thomsen LL: Nitric oxide super-sensitivity, A possible molecular mechanism of migraine pain, Neuroreport 1993:4:1027-1030.
69. Olesen J, Saxena PR (eds): 5-Hydroxytryptamine mechanisms in primary headache, New York, Raven Press, 1992.
70. Phelps ME, Kuhl DE: Metabolic mapping of the brain's response to visual stimulation: Studies in humans, Science 1981:211:1445-1448.
71. Prichard JW, Rothman DL, Novotny E, Petroff AC, Kuwabara T, Avison M, Howseman A, Hanstock CC, Shuhnan RG: Lactate rise detected by III NMR in human visual cortex during physiologic stimulation, Proc Nat Acad Sci USA 1991:88:5829-5831.
72. Ramadan NM: Halvorsen H, Vande-Linde A, Levine SR, Helpern JA, Welch KMA: Low brain magnesium in migraine, Headache 1989:29:590-593.
73. Rebert CS: Cortical and subcortieal slow potentials in the monkey's brain during a preparatory interval, Elec-troenceph Clin Ncurophysiol 1972:33:389-402.
74. Rebert CS, Tecce JJ, Marcvnski TJ, Pirch JII, Thompson JW: Neural anatomy chemistry and event-related brain potentials: An approach to understanding the substrates of mind: in McCallum WC, Zappoli R, De-noth F (eds): Cerebral Psychophysiology: Studies in Event-Related Potentials, New York, Elsevier, 1986, pp 343-392.
75. Rockstroh B, Elbert T, Canavan A, Lutzenberger W, Birbaumer N: Slow cortical potentials and behaviour (2nd ed) Baltimore, MD, Urban & Schwarzcnberg, 1989.
76. Rockstroh B, Elbert T, Lutzenberger W, Birbaumer N: Operant control of slow brain potentials: A tool in the investigation of the potential’s meaning and its relation to attentional dysfunction: in Rockstroh B, Lutzenberger W, Birbaumer N (eds): Self-Regulation of Brain and Behavior, Berlin, Springer, 1984, pp 227-242.
77. Robinson I E, Berridge KC: The neural basis of drug craving: An incentivc-sensitisation theory of addiction, Brain Res Rev 1993:18:247-291.
78. Rohrbaugh JW, McCallum WC, Gaillard AWK, Simons RF, Birbaumer N, Papakostopopoulos D: ERPs associated with preparatory and movement-related processes, A review: in McCallum WC, Zappoli R, De-noth F (eds): Cerebral Psychophysiology: Studies in Event-Related Potentials, New York, Elsevier, 1986, pp 189-231.
79. Routtenberg A: Das Belohnungssystem des Gehirns: in Gehirn und Nervensystem, Heidelberg, Spektrum, 1988, pp 160-167.
80. Sand T: EEG in migraine: A review of the literature, Funct Neurol 1991:6:7-22.
81. Sangiorgi S, Mochi M, Riva R, Cortelli P, Monari L, Pierangeli G, Montagna P: Abnormal platelet mitochondrial function in patients affected by migraine with and without aura, Cephalalgia 1994:14:21-23.
82. Sappev-Marinier D, Calabrese G, Fein G, Hugg JW, Biggins C, Weiner MW: Effect of photic stimulation on human visual cortex lactate and phosphates using IH and 31P magnetic resonance spectroscopy, J C'ereb Blood Flow Met 1992:12:584-592.
83. Sartory G: The contingent negative variation (CNV) in psychiatric states: in Martin I, Papakostopoulos D (eds): Clinical and experimental neuropsychology, London, Croom Helm, 1986, pp 286-311.
84. Sartory G, Besken E, Pothmann R: Slow cortical potentials in childhood migraine (submitted).
85. Schedenberg R, Bölsche F, Schwarz A, Thom VI, Gerber WD, Niedergerber U, Soyka D, Wedekind W: Cyc-landclate versus propranolol clinical and neurophy-siological control of therapeutic efficacy in the prophylaxis of migraine - results of a double blind study: in Clifford Rose F (ed): New Advances in Headache Research, London, Smith-Gorden, 1994, pp 141-148.
86. Schoenen J: Clinical neurophysiology studies in headache: A review of data and pathophysiological hints, Funct Neurol 1992:7:191-204.
87. Schoenen J, Barkley GL: Neurophysiology: in Olesen J, Tfelt-Hansen P, Welch KMA (eds): The Headaches, New York, Raven Press, 1993, pp 199-208.
88. Schoenen J, Maertens de Noordhout A: The role of the sympathetic nervous system in migraine and cluster headache: in Olesen J, Edvinsson L (eds): Basic Mechanisms of Headache Pain Research and Management, Amsterdam, Elsevier, 1988, vol 2, pp 393-410.
89. Schoenen J, Maertens de Noordhout A, Timsit-Ber-thier M, Ilmsit M: Contingent negative variation (CNV) as a diagnostic and physiopathologic tool in headache patients: in Clifford Rose F (ed): Migraine: Clinical and Research Advances, Basel, Karger, 1985, pp 17-25.
90. Schoenen J, Maertens de Noordhout A, Timsit-Ber-thier M, Timsit M: Contingent negative variation and efficacy of beta-blocking agents in migraine, Cephalalgia 1986:6:229-233.
91. Seligman M: Helplessness on depression, development and death, San Francisco, Freeman, 1975.
92. Sikuteri F: Pain and vegetative automatisms in migraine as speculated through cannon's law, Funct Neurol 1989:4(suppl I):41-103.
93. Sikuteri F, Nicolodi M: Perfection craving: Instability of modulation as a ground for spontaneous (migraine) or pharmacological (addiction) diseases, Cephalalgia 1995:15(suppl 14):191 (abstr).
94. Siniatchkin MS, Vosnesenskaya TG, Kolosova OA: Changes of CNV during headache-free interval, Funct Neurol 1996:11:145(abstr).
95. Siniatchkin MS, Gerber WD, Vein A: Cyclandclate in migraine: Clinical efficacy' and central mechanisms (submitted).
96. Sorensen SA, Araki S: Headaches: Genetics: in Olesen J, Tfelt-Hansen P, Welch KMA (eds): The Headaches, New York, Rvaen Press, 1993, pp 511-512.
97. Stellar JR, Stellar E: The Neurobiology of Motivation and Reward, New York, Springer, 1985.
98. Tecce JJ: Dopamine and CNV: Studies of drugs, disease and nutrition: in Brunia CHM, Mulder G (eds): Event-Related Brain Research, Verbaten M.N., 1991, pp 153-164.
99. Tecce JJ, Savignano-Bowman J, Cole JO: Drug effects on contingent negative variation and eyeblinks: The distruction-arousal hypothesis: in Lipton MA, DiMas-cio A, Killam KF (eds): Psychopharmacology: A generation of progress, New York, Raven Press, 1978, pp 745-758.
100. Thoden U, Wiehert N: Grenzen und Möglichkeiten neurophysiologischcr Methoden in der Erforschung und Diagnostik der Migräne, Schmerz 1991:5:1-8.
101. Thompson JW: Preliminary study of pharmacology of CNV in man: in Ott D (ed): Multidisciplinary Perspectives in Event-Related Brain Potentials Research, Washington, DC, US Environmental Protection Agency, 1978, pp 51-55.
102. Timsit-Berthicr M, Mantanus H, Poncelet M, Maris-saux P, Legros J: Contigent negative variation as a new method to assess the catccholamincrgic system: in Gal-lai V (ed): Maturation of the CNS and Evoked Potentials, Amsterdam, Elsevier, 1989.
103. Timsit-Berthier M, Delaunoy J, Xhcnseval B, Timsit M: Reliability of contingent negative variation in psychiatry: in Otlo DA (ed): Multidisciplinary perspectives in event-related brain potential research, Washington, DC, US Environmental Protection Agency, 1978, pp 373-375.
104. Uncini A, Lodi R, Di Muzio A, Silvestri G, Scrvidei S, Lugaresi A, lotti S, Zaniol P, Barbiroli B: Abnormal brain anc muscle energy metabolism shown by 31-MRS in familial hemiplegic migraine, J Neurol Sci 1995:129:214-222.
105. Wallasch I, Kropp P, Weinschütz T, König B: Contingent negative variation in tension-type headache: in Olesen J, Schoenen J (eds): Tension-Type Headache: Classification Mechanisms and Treatment, New York, Raven Press, 1993.
106. Wang W, Schoenen J, Maertens de Noordhout A, Dcl-waide PJ: Intensity dependence of auditory evoked potentials in migraine, Neurology 1995:45(suppl 4):A464-1078P.
107. Welch KMA: Migraine: A biobehavioral disorder, Cephalalgia 1986;6(suppl 4): 103-110.
108. Welch KMA, Levine SR, D'Andrea G, Helpern JA: Brain pH in migraine: An in vivo phosphorus-31 magnetic resonance spectroscopy study, Cephalalgia 1988:8:273-277.
109. Welch KMA, Levine SR, D'Andrea CJ, Schultz L, Helpern JA: Preliminary observations on brain energy metabolism in migraine studied by in vivo 31 phosphorus NMR spectroscopy, Neurology 1989:39:538-541.
110. Whybrow PC, Akiskal HS, McKinney WT: Mood disorders, New York, Plenum, 1984.
111. Wise RA, Rompre PP: Brain dopamine and reward, Ann Rev Psychol 1989:40:191-225.